To Evaluate the Safety and Efficacy of RNK08954 in Patients With Metastatic Pancreatic Ductal Adenocarcinoma.

Clinical trial NCT07303465 · RECRUITING

Trial details

NCT number: NCT07303465
Sponsor: Ranok Therapeutics (Hangzhou) Co., Ltd.
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

KRAS G12D Mutations Pancreatic Ductal Adenocarcinoma (PDAC)

Start date: 2025-10-14
Primary completion: 2026-11-30
Enrollment: 60

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.